The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Gabexate mesilate ameliorates the neuropathic pain in a rat model by inhibition of proinflammatory cytokines and nitric oxide pathway via suppression of nuclear factor-κB

  • Oh, Seon Hee (School of Medicine, Chosun University) ;
  • Lee, Hyun Young (Department of Anesthesiology and Pain Medicine, Chosun University Hospital) ;
  • Ki, Young Joon (Department of Anesthesiology and Pain Medicine, Chosun University Hospital) ;
  • Kim, Sang Hun (Department of Anesthesiology and Pain Medicine, Chosun University Hospital) ;
  • Lim, Kyung Joon (Department of Anesthesiology and Pain Medicine, Chosun University Hospital) ;
  • Jung, Ki Tae (Department of Anesthesiology and Pain Medicine, Chosun University Hospital)
  • Received : 2019.08.23
  • Accepted : 2019.11.03
  • Published : 2020.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: This study examined the effects of gabexate mesilate on spinal nerve ligation (SNL)-induced neuropathic pain. To confirm the involvement of gabexate mesilate on neuroinflammation, we focused on the activation of nuclear factor-κB (NF-κB) and consequent the expression of proinflammatory cytokines and inducible nitric oxide synthase (iNOS). Methods: Male Sprague-Dawley rats were used for the study. After randomization into three groups: the sham-operation group, vehicle-treated group (administered normal saline as a control), and the gabexate group (administered gabexate mesilate 20 mg/kg), SNL was performed. At the 3rd day, mechanical allodynia was confirmed using von Frey filaments, and drugs were administered intraperitoneally daily according to the group. The paw withdrawal threshold (PWT) was examined on the 3rd, 7th, and 14th day. The expressions of p65 subunit of NF-κB, interleukin (IL)-1, IL-6, tumor necrosis factor-α, and iNOS were evaluated on the 7th and 14th day following SNL. Results: The PWT was significantly higher in the gabexate group compared with the vehicle-treated group (P < 0.05). The expressions of p65, proinflammatory cytokines, and iNOS significantly decreased in the gabexate group compared with the vehicle-treated group (P < 0.05) on the 7th day. On the 14th day, the expressions of p65 and iNOS showed lower levels, but those of the proinflammatory cytokines showed no significant differences. Conclusions: Gabexate mesilate increased PWT after SNL and attenuate the progress of mechanical allodynia. These results seem to be involved with the antiinflammatory effect of gabexate mesilate via inhibition of NF-κB, proinflammatory cytokines, and nitric oxide.

Keywords

References

  1. Gao J, Tang C, Tai LW, Ouyang Y, Li N, Hu Z, et al. Pro-resolving mediator maresin 1 ameliorates pain hypersensitivity in a rat spinal nerve ligation model of neuropathic pain. J Pain Res 2018; 11: 1511-9. https://doi.org/10.2147/JPR.S160779
  2. Oh SH, So HJ, Lee HY, Lim KJ, Yoon MH, Jung KT. Urinary trypsin inhibitor attenuates the development of neuropathic pain following spinal nerve ligation. Neurosci Lett 2015; 590: 150-5. https://doi.org/10.1016/j.neulet.2015.01.070
  3. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 2008; 153: 319-34. https://doi.org/10.1038/sj.bjp.0707531
  4. Sacerdote P, Franchi S, Moretti S, Castelli M, Procacci P, Magnaghi V, et al. Cytokine modulation is necessary for efficacious treatment of experimental neuropathic pain. J Neuroimmune Pharmacol 2013; 8: 202-11. https://doi.org/10.1007/s11481-012-9428-2
  5. Austin PJ, Moalem-Taylor G. The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J Neuroimmunol 2010; 229: 26-50. https://doi.org/10.1016/j.jneuroim.2010.08.013
  6. Jha MK, Jeon S, Suk K. Glia as a link between neuroinflammation and neuropathic pain. Immune Netw 2012; 12: 41-7. https://doi.org/10.4110/in.2012.12.2.41
  7. Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev 2006; 51: 240-64. https://doi.org/10.1016/j.brainresrev.2005.11.004
  8. Zelenka M, Schafers M, Sommer C. Intraneural injection of interleukin-1beta and tumor necrosis factor-alpha into rat sciatic nerve at physiological doses induces signs of neuropathic pain. Pain 2005; 116: 257-63. https://doi.org/10.1016/j.pain.2005.04.018
  9. Myers RR, Campana WM, Shubayev VI. The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets. Drug Discov Today 2006; 11: 8-20. https://doi.org/10.1016/S1359-6446(05)03637-8
  10. Schafers M, Brinkhoff J, Neukirchen S, Marziniak M, Sommer C. Combined epineurial therapy with neutralizing antibodies to tumor necrosis factor-alpha and interleukin-1 receptor has an additive effect in reducing neuropathic pain in mice. Neurosci Lett 2001; 310: 113-6. https://doi.org/10.1016/S0304-3940(01)02077-8
  11. Sommer C, Petrausch S, Lindenlaub T, Toyka KV. Neutralizing antibodies to interleukin 1-receptor reduce pain associated behavior in mice with experimental neuropathy. Neurosci Lett 1999; 270: 25-8. https://doi.org/10.1016/S0304-3940(99)00450-4
  12. Park JH, Kwak SH, Jeong CW, Bae HB, Kim SJ. Effect of ulinastatin on cytokine reaction during gastrectomy. Korean J Anesthesiol 2010; 58: 334-7. https://doi.org/10.4097/kjae.2010.58.4.334
  13. Moggia E, Koti R, Belgaumkar AP, Fazio F, Pereira SP, Davidson BR, et al. Pharmacological interventions for acute pancreatitis. Cochrane Database Syst Rev 2017; 4: CD011384.
  14. Jung KT, Lee HY, Yoon MH, Lim KJ. The effect of urinary trypsin inhibitor against neuropathic pain in rat models. Korean J Pain 2013; 26: 356-60. https://doi.org/10.3344/kjp.2013.26.4.356
  15. Taoka Y, Okajima K, Uchiba M, Murakami K, Kushimoto S, Johno M, et al. Gabexate mesilate, a synthetic protease inhibitor, prevents compression-induced spinal cord injury by inhibiting activation of leukocytes in rats. Crit Care Med 1997; 25: 874-9. https://doi.org/10.1097/00003246-199705000-00026
  16. Shih RH, Wang CY, Yang CM. NF-kappaB signaling pathways in neurological inflammation: a mini review. Front Mol Neurosci 2015; 8: 77. https://doi.org/10.3389/fnmol.2015.00077
  17. Colasanti M, Persichini T, Venturini G, Menegatti E, Lauro GM, Ascenzi P. Effect of gabexate mesylate (FOY), a drug for serine proteinase-mediated diseases, on the nitric oxide pathway. Biochem Biophys Res Commun 1998; 246: 453-6. https://doi.org/10.1006/bbrc.1998.8642
  18. Carrasco C, Naziroglu M, Rodriguez AB, Pariente JA. Neuropathic pain: delving into the oxidative origin and the possible implication of transient receptor potential channels. Front Physiol 2018; 9: 95.
  19. Freire MA, Guimaraes JS, Leal WG, Pereira A. Pain modulation by nitric oxide in the spinal cord. Front Neurosci 2009; 3: 175-81. https://doi.org/10.3389/neuro.01.024.2009
  20. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16: 109-10. https://doi.org/10.1016/0304-3959(83)90201-4
  21. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992; 50: 355-63. https://doi.org/10.1016/0304-3959(92)90041-9
  22. Chung JM, Kim HK, Chung K. Segmental spinal nerve ligation model of neuropathic pain. Methods Mol Med 2004; 99: 35-45.
  23. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53: 55-63. https://doi.org/10.1016/0165-0270(94)90144-9
  24. Thacker MA, Clark AK, Marchand F, McMahon SB. Pathophysiology of peripheral neuropathic pain: immune cells and molecules. Anesth Analg 2007; 105: 838-47. https://doi.org/10.1213/01.ane.0000275190.42912.37
  25. Uceyler N, Sommer C. Cytokine regulation in animal models of neuropathic pain and in human diseases. Neurosci Lett 2008; 437: 194-8. https://doi.org/10.1016/j.neulet.2008.03.050
  26. Gao YJ, Zhang L, Samad OA, Suter MR, Yasuhiko K, Xu ZZ, et al. JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J Neurosci 2009; 29: 4096-108. https://doi.org/10.1523/JNEUROSCI.3623-08.2009
  27. Shamash S, Reichert F, Rotshenker S. The cytokine network of Wallerian degeneration: tumor necrosis factor-alpha, interleukin-1alpha, and interleukin-1beta. J Neurosci 2002; 22: 3052-60. https://doi.org/10.1523/jneurosci.22-08-03052.2002
  28. Leung L, Cahill CM. TNF-alpha and neuropathic pain--a review. J Neuroinflammation 2010; 7: 27. https://doi.org/10.1186/1742-2094-7-27
  29. Gui WS, Wei X, Mai CL, Murugan M, Wu LJ, Xin WJ, et al. Interleukin-$1{\beta}$ overproduction is a common cause for neuropathic pain, memory deficit, and depression following peripheral nerve injury in rodents. Mol Pain 2016; 12: 1744806916646784.
  30. Li X, Wang J, Wang Z, Dong C, Dong X, Jing Y, et al. Tumor necrosis factor-$\alpha$ of red nucleus involved in the development of neuropathic allodynia. Brain Res Bull 2008; 77: 233-6. https://doi.org/10.1016/j.brainresbull.2008.08.025
  31. Ding CP, Xue YS, Yu J, Guo YJ, Zeng XY, Wang JY. The red nucleus interleukin-6 participates in the maintenance of neuropathic pain induced by spared nerve injury. Neurochem Res 2016; 41: 3042-51. https://doi.org/10.1007/s11064-016-2023-9
  32. Lu Y, Cao DL, Jiang BC, Yang T, Gao YJ. MicroRNA-146a-5p attenuates neuropathic pain via suppressing TRAF6 signaling in the spinal cord. Brain Behav Immun 2015; 49: 119-29. https://doi.org/10.1016/j.bbi.2015.04.018
  33. Lu Y, Jiang BC, Cao DL, Zhang ZJ, Zhang X, Ji RR, et al. TRAF6 upregulation in spinal astrocytes maintains neuropathic pain by integrating TNF-$\alpha$ and IL-$1{\beta}$ signaling. Pain 2014; 155: 2618-29. https://doi.org/10.1016/j.pain.2014.09.027
  34. Lin TB, Hsieh MC, Lai CY, Cheng JK, Chau YP, Ruan T, et al. Fbxo3-dependent Fbxl2 ubiquitination mediates neuropathic allodynia through the TRAF2/TNIK/GluR1 cascade. J Neurosci 2015; 35: 16545-60. https://doi.org/10.1523/JNEUROSCI.2301-15.2015
  35. Levy D, Zochodne DW. NO pain: potential roles of nitric oxide in neuropathic pain. Pain Pract 2004; 4: 11-8. https://doi.org/10.1111/j.1533-2500.2004.04002.x
  36. Liu DL, Zhao LX, Zhang S, Du JR. Peroxiredoxin 1-mediated activation of TLR4/NF-${\kappa}B$ pathway contributes to neuroinflammatory injury in intracerebral hemorrhage. Int Immunopharmacol 2016; 41: 82-9. https://doi.org/10.1016/j.intimp.2016.10.025
  37. Pei W, Zou Y, Wang W, Wei L, Zhao Y, Li L. Tizanidine exerts anti-nociceptive effects in spared nerve injury model of neuropathic pain through inhibition of TLR4/NF-${\kappa}B$ pathway. Int J Mol Med 2018; 42: 3209-19.
  38. Lee KM, Kang BS, Lee HL, Son SJ, Hwang SH, Kim DS, et al. Spinal NF-kB activation induces COX-2 upregulation and contributes to inflammatory pain hypersensitivity. Eur J Neurosci 2004; 19: 3375-81. https://doi.org/10.1111/j.0953-816X.2004.03441.x
  39. Meunier A, Latremoliere A, Dominguez E, Mauborgne A, Philippe S, Hamon M, et al. Lentiviral-mediated targeted NF-kappaB blockade in dorsal spinal cord glia attenuates sciatic nerve injury-induced neuropathic pain in the rat. Mol Ther 2007; 15: 687-97. https://doi.org/10.1038/sj.mt.6300107
  40. Brambilla R, Bracchi-Ricard V, Hu WH, Frydel B, Bramwell A, Karmally S, et al. Inhibition of astroglial nuclear factor kappaB reduces inflammation and improves functional recovery after spinal cord injury. J Exp Med 2005; 202: 145-56. https://doi.org/10.1084/jem.20041918
  41. Rivot JP, Montagne-Clavel J, Besson JM. Subcutaneous formalin and intraplantar carrageenan increase nitric oxide release as measured by in vivo voltammetry in the spinal cord. Eur J Pain 2002; 6: 25-34. https://doi.org/10.1053/eujp.2001.0268
  42. Schomberg D, Ahmed M, Miranpuri G, Olson J, Resnick DK. Neuropathic pain: role of inflammation, immune response, and ion channel activity in central injury mechanisms. Ann Neurosci 2012; 19: 125-32.
  43. Gao X, Kim HK, Chung JM, Chung K. Reactive oxygen species (ROS) are involved in enhancement of NMDA-receptor phosphorylation in animal models of pain. Pain 2007; 131: 262-71. https://doi.org/10.1016/j.pain.2007.01.011
  44. Inoue T, Mashimo T, Shibata M, Shibuta S, Yoshiya I. Rapid development of nitric oxide-induced hyperalgesia depends on an alternate to the cGMP-mediated pathway in the rat neuropathic pain model. Brain Res 1998; 792: 263-70. https://doi.org/10.1016/S0006-8993(98)00147-4
  45. Roche AK, Cook M, Wilcox GL, Kajander KC. A nitric oxide synthesis inhibitor (L-NAME) reduces licking behavior and Fos-labeling in the spinal cord of rats during formalininduced inflammation. Pain 1996; 66: 331-41. https://doi.org/10.1016/0304-3959(96)03025-4
  46. Lee HL, Lee KM, Son SJ, Hwang SH, Cho HJ. Temporal expression of cytokines and their receptors mRNAs in a neuropathic pain model. Neuroreport 2004; 15: 2807-11. https://doi.org/10.1097/00001756-200412220-00024
  47. Roytta M, Wei H, Pertovaara A. Spinal nerve ligation-induced neuropathy in the rat: sensory disorders and correlation between histology of the peripheral nerves. Pain 1999; 80: 161-70. https://doi.org/10.1016/S0304-3959(98)00199-7